Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis

Abstract

Get full access to this article

View all access options for this article.

References

Gelfand

Cree

Hauser

SL.

Ocrelizumab and other CD20+ B-cell-depleting therapies in multiple sclerosis. Neurotherapeutics 2017; 14: 835–841.

Hauser

Waubant

Arnold

et al . B-cell Depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676–688.

Salzer

Svenningsson

Alping

et al . Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy. Neurology 2016; 87: 2074–2081.

Granqvist

Boremalm

Poorghobad

et al . Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurol. Epub ahead of print 2018. DOI: 10.1001/jamaneurol.2017.4011

Hauser

Bar-Or

Comi

et al . Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 2017; 376: 221–234.

Montalban

Hauser

Kappos

et al . Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017; 376: 209–220.

Klein

Lammenas

Schafe

et al . Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs 2013; 5: 22–33.

Naismith

Piccio

Lyons

et al . Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial. Neurology 2010; 74: 186–1867.

Hawker

OConnor

Freedman

et al . Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66: 460–471.

10.

Clifford

Ances

Costello

et al . Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 2011; 68: 1156–1164.

11.

Hartung

Bourdette

Ahmed

et al . The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail? Neurology 2015; 84: 2185–2192.

12.

Tolerability and safety of switching from rituximab to ocrelizumab in patients with relapsing forms of multiple sclerosis, NCT02980042, University of Colorado, Denver, CO, Clinicaltrials.gov (accessed 13 January 2018).

Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis – No

Abstract

Get full access to this article

References